GLSHQ (Gelesis Holdings) Pretax Margin %: -693.86% (As of Jun. 2023)


What is Gelesis Holdings Pretax Margin %?

Gelesis Holdings GLSHQ -99.00% Pretax Margin % is -693.86% as of Jun. 2023.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Gelesis Holdings's Pre-Tax Income for the three months ended in Jun. 2023 was $-7.68 Mil. Gelesis Holdings's Revenue for the three months ended in Jun. 2023 was $1.11 Mil. Therefore, Gelesis Holdings's pretax margin for the quarter that ended in Jun. 2023 was -693.86%.

The historical rank and industry rank for Gelesis Holdings's Pretax Margin % or its related term are showing as below:


GLSHQ's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.63
* Ranked among companies with meaningful Pretax Margin % only.

Gelesis Holdings  (OTCPK:GLSHQ) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Gelesis Holdings Pretax Margin % Related Terms

Gelesis Holdings Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Pretax Margin % Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Pretax Margin %
-834.42 -214.62

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -139.45 -212.70 -872.72 -292.64 -693.86

GLSHQ vs RBSH, PPCB, RGMP: Pretax Margin % Comparison

For the Biotechnology subindustry, Gelesis Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's Pretax Margin % falls into.


Gelesis Holdings Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Gelesis Holdings's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-55.3/25.767
=-214.62 %

Gelesis Holdings's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-7.681/1.107
=-693.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -693.86% mean?
Gelesis Holdings (GLSHQ) has a Pretax Margin % of -693.86% as of Jun. 2023. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Pretax Margin % too high?
Gelesis Holdings' current Pretax Margin % is -693.86%.
How does Gelesis Holdings' Pretax Margin % compare to RBSH and PPCB?
Gelesis Holdings' Pretax Margin % of -693.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Gelesis Holdings and its competitors. Gelesis Holdings's current Pretax Margin % is -693.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Pretax Margin % of -693.86%. The current Pretax Margin % is -693.86%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Pretax Margin % is -693.86% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.